← Back to Search

Monoclonal Antibodies

IDP-023 + Antibody Therapies for Blood Cancers

Phase 1 & 2
Recruiting
Research Sponsored by Indapta Therapeutics, INC.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
For MM patients: Documented diagnosis of MM requiring systemic therapy and relapsed and/or refractory (R/R) disease after ≥ 3 prior lines of therapy.
For NHL patients: R/R disease and failed ≥ 2 lines of systemic chemotherapy.
Must not have
Active SARS-CoV-2 infection.
Impaired cardiac function or history of clinical significant cardiac disease.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights
No Placebo-Only Group

Summary

This trial tests IDP-023, a treatment using special immune cells to fight cancer, in patients with advanced multiple myeloma or non-Hodgkin's lymphoma who haven't responded to other treatments. IDP-023 is part of a broader category of immunotherapies that have shown promise in treating multiple myeloma and non-Hodgkin's lymphoma.

Who is the study for?
This trial is for adults with advanced blood cancers like Non-Hodgkin's Lymphoma or Multiple Myeloma who have tried at least two or three treatments without success. They should be relatively healthy otherwise, with a life expectancy over 12 weeks and able to perform daily activities with little to no assistance.
What is being tested?
The study tests IDP-023 alone and combined with other drugs (Rituximab, Daratumumab) in different stages. It aims to find the safest dose that works best against these cancers. Some patients will also receive IL-2, Cyclophosphamide, Fludarabine, and Mesna as part of their treatment combinations.
What are the potential side effects?
Possible side effects include reactions related to the immune system such as fever and chills, potential damage to organs from inflammation caused by the drug combination, fatigue from treatment-related anemia or general body stress, nausea due to chemotherapy agents used alongside IDP-023.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have multiple myeloma that has not responded to 3 or more treatments.
Select...
I have non-Hodgkin lymphoma that didn't respond to at least 2 chemotherapy treatments.
Select...
I am fully active or restricted in physically strenuous activity but can do light work.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am currently infected with COVID-19.
Select...
I have heart problems or a history of significant heart disease.
Select...
I have HIV, active hepatitis B, or hepatitis C.
Select...
I have untreated brain or spinal cord tumor spread.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
For MM: Anti-tumor activity by objective response rate (ORR), complete response (CR), stringent complete response (sCR), very good partial response (VGPR), and partial response (PR) - (Phase 2)
For NHL: Anti-tumor activity by objective response rate (ORR) - (Phase 2)
Incidence of adverse events (AEs) and serious adverse events (SAEs) - (Phase 1)
+5 more
Secondary study objectives
For MM: Anti-tumor activity by objective response rate (ORR), complete response (CR), stringent complete response (sCR), very good partial response (VGPR), and partial response (PR) - (Phase 1)
For NHL: Anti-tumor activity by objective response rate (ORR) - (Phase 1)
Incidence of adverse events (AEs) and serious adverse events (SAEs) - (Phase 2)
+2 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

5Treatment groups
Experimental Treatment
Group I: Phase 2: Combination IDP-023 plus rituximabExperimental Treatment6 Interventions
NHL patients treated with multiple doses of IDP-023 in combination with rituximab
Group II: Phase 2: Combination IDP-023 plus daratumumabExperimental Treatment6 Interventions
MM patients treated with multiple doses of IDP-023 in combination with daratumumab
Group III: Phase 1: Single Agent IDP-023 - Single DoseExperimental Treatment4 Interventions
NHL or MM patient treated with a single dose of IDP-023 monotherapy
Group IV: Phase 1: Single Agent IDP-023 - Multiple Doses with IL-2Experimental Treatment5 Interventions
NHL and MM patients treated with multiple doses of IDP-023 monotherapy
Group V: Phase 1: Single Agent IDP-023 - Multiple DosesExperimental Treatment4 Interventions
NHL and MM patients treated with multiple doses of IDP-023 monotherapy
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Mesna
2003
Completed Phase 2
~1380
Interleukin-2
1994
Completed Phase 3
~690
Rituximab
1999
Completed Phase 4
~2990
Daratumumab
2014
Completed Phase 3
~2380
Cyclophosphamide
2010
Completed Phase 4
~2310
Fludarabine
2012
Completed Phase 4
~1860

Find a Location

Who is running the clinical trial?

Indapta Therapeutics, INC.Lead Sponsor
1 Previous Clinical Trials
34 Total Patients Enrolled
Indapta Therapeutics, Inc.Study DirectorIndapta Therapeutics, INC.
1 Previous Clinical Trials
34 Total Patients Enrolled
~59 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top